MMED
Get informed when a big investor buys or sells
+ FollowUndervalued by 166.4% based on the discounted cash flow analysis.
| Market cap | $4.75 Billion |
|---|---|
| Enterprise Value | $4.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.29 |
| Beta | -3.63 |
| Outstanding Shares | 268,100,000 |
| P/E Ratio | -15.39 |
|---|---|
| PEG | 123.72 |
| Price to Sales | - |
| Price to Book Ratio | 1.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 11.55% |
|---|---|
| Total Invested | $402,515▼ 99.92% |
| Investors Holding | 3▼ 57.00% |
No data
MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion s...